EW Q2 2023 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q2 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.3B-5.7% YoY

Gross Profit

$1.0B79.1% margin

Operating Income

$371M28.6% margin

Net Income

$307M23.7% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

-11.2%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

-$14M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$9.0B

Total Liabilities

$2.6B

Stockholders' Equity

$6.4B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.4B	-5.7%
Gross Profit	$1.0B	$1.1B	-5.8%
Operating Income	$371M	$428M	-13.5%
Net Income	$307M	$406M	-24.4%

Revenue Segments

Transcatheter Heart Valves

$992M65%

Surgical Heart Valve Therapy

$256M17%

Critical Care

$235M15%

Transcatheter Mitral And Tricuspid Therapies

$48M3%

Geographic Segments

UNITED STATES

$895M59%

Europe

$336M22%

Rest of World

$181M12%

JAPAN

$118M8%